文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

双静脉青蒿琥酯联合奎宁对比单用青蒿琥酯治疗尼日利亚儿童脑型疟疾的三盲平行多中心随机对照试验:DUAL PAQ试验方案

Efficacy and safety of dual intravenous artesunate plus quinine compared to intravenous artesunate for cerebral malaria in a triple blinded parallel multisite randomized controlled trial in Nigerian children: DUAL PAQ TRIAL Protocol.
PubMed 文献 · Trials · 2021-10-20

本研究为三盲平行多中心随机对照优效性试验方案,在尼日利亚4家三级医院招募6月龄至17岁脑型疟疾患儿,随机分配至静脉青蒿琥酯联合奎宁组或单用青蒿琥酯组。主要结局为随机化后12、24、48小时生存率,复合次要结局包括意识恢复、疟原虫血症、退热及血液学和炎症标志物。方案已获伦理批准并注册,旨在评估双静脉抗疟药联合方案的有效性与安全性。

要点

  • 脑型疟疾当前单药初始治疗病死率达35%,亟需更优方案。
  • 该试验为三盲平行多中心随机对照优效性设计,比较双药联合与单药。
  • 主要结局为随机化后12、24、48小时生存率,并系统记录不良事件。

核心结论

  • 本方案拟评估静脉青蒿琥酯联合奎宁对比单用青蒿琥酯治疗尼日利亚儿童脑型疟疾的有效性与安全性。

研究设计与样本

  • 三盲平行多中心随机对照优效性试验,从尼日利亚4家三级医院随机选取并招募6月龄至17岁合格且同意的儿童。
  • 由与研究者、患者和统计师无关联的临床药理学家用GraphPad Prism版本9生成随机数,将参与者平行随机分配至两组。

主要发现

  • 原文为试验方案,未报告试验结果。

关键数值与推荐

  • 主要可测量结局为随机化后12、24、48小时生存率。
  • 复合次要结局包括随机化后12和24小时意识恢复、疟原虫血症和退热的儿童数量,以及随机化后24和48小时血液学和炎症标志物。
  • 研究全程记录随机化后主动询问和非主动报告的不良事件。

临床怎么用

  • 该分析结果将揭示双静脉抗疟药治疗尼日利亚儿童脑型疟疾相较标准治疗的有效性与安全性,或有助于医生优化治疗、改善结局并减少再燃和治疗失败。

局限性

  • 原文为试验方案,尚未提供疗效与安全性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence exists as to the criticality of the first 24 h in the management of cerebral malaria. The morbidity and the mortality rate (35%) with the current intravenous monotherapy for the initial treatment of cerebral malaria are unacceptably high. Combination therapy and a shorter course of effective medication have been shown to improve outcomes in human participants in the treatment of other diseases. This study outlines a protocol to conduct a triple blinded parallel randomized controlled trial on cerebral malaria using dual intravenous medications compared to the current standard of monotherapy. METHODS: This is a parallel multi-site randomized controlled superiority triple blinded trial consisting of intravenous artesunate plus quinine and a control arm of intravenous artesunate only. Eligible and assenting children aged 6 months to 17 years will be recruited from 4 tertiary hospitals by random selection from the list of tertiary hospitals in Nigeria. Participants will be randomized and assigned in parallel into two arms using random numbers generated from GraphPad Prism (version 9) by a clinical pharmacologist who has no link with the investigators, the patients, or the statistician. The primary measurable outcome is survival at 12, 24, and 48 h post-randomization. A composite secondary outcome consists of the number of children that regained consciousness, parasitaemia and defervescence at 12 and 24 h post-randomization and haematological and inflammatory markers at 24 and 48 h post-randomization. Adverse events both solicited and unsolicited are recorded all through the study post-randomization. The study is approved by the State Research Ethics Review Committee. Data analysis will be performed in GraphPad Prism version 9. DISCUSSION: The outcome of this analysis will give insight into the efficacy and safety of dual intravenous antimalaria in the treatment of cerebral malaria among Nigerian children compared with the standard of care. The safety profile of this intervention will also be highlighted. This may help inform physicians on the optimal treatment for cerebral malaria to improve outcomes and reduce recrudescence and treatment failure. TRIAL REGISTRATION: Pan Africa Clinical Trial Registry PACTR202102893629864 . 23/02/2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Alao MA, Orimadegun AE, Ibrahim OR, et al. Efficacy and safety of dual intravenous artesunate plus quinine compared to intravenous artesunate for cerebral malaria in a triple blinded parallel multisite randomized controlled trial in Nigerian children: DUAL PAQ TRIAL Protocol. Trials. 2021. PMID: 34670598. doi:10.1186/s13063-021-05634-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。